ACLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arcellx Inc (ACLX) is not a good buy for a long-term beginner investor at this time. The stock is trading at $115, which aligns with the acquisition price set by Gilead. With no significant upside potential and analysts downgrading the stock to Neutral or Hold due to the acquisition, there is limited room for growth. Additionally, insider selling and declining financial performance further reduce its appeal.
The stock shows neutral to slightly bullish technical indicators. The MACD is below 0 but negatively contracting, and RSI is neutral at 71.037. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the price is hovering near resistance levels (R1: 115.097).
The acquisition by Gilead has secured all regulatory approvals, and 18% of shares have been tendered, indicating progress toward deal closure.
Insiders are selling heavily, with a 642.87% increase in selling over the last month. Analysts have downgraded the stock to Neutral or Hold, citing no competing offers and limited upside beyond the acquisition price.
In Q4 2025, revenue dropped by 89.17% YoY to $1.65M. Net income improved by 23.43% YoY but remains negative at -$58.11M. EPS improved to -1, up 14.94% YoY. Gross margin remained flat at 100%. Overall, financials show declining revenue and persistent losses.
Analysts have downgraded the stock to Neutral or Hold, with a price target of $115, aligning with Gilead's acquisition price. No competing offers are expected, and the deal is anticipated to close in Q2 2026.
